[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-hodgkin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-hodgkin":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100500742","phase-2-alphabeta-t-cell-and-cd19-b-cell-depletion-in-allogeneic-stem-cell-transplantation-in-patients-with-malignant-diseases-100500742",false,"NCT05800210","Alpha\u002FBeta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases","Inclusion Criteria:\n\nA. Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible:\n\ni. ALL\n\n1. ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission\n2. ALL in second remission and beyond\n\nii. AML\n\n1. History of AML induction\u002Freinduction Failure (≤15% blasts at time of registration)\n2. AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation\u002Fduplication, t(9;11) and others)\n3. AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)\n4. AML CR2 or beyond\n5. AML in refractory relapse but ≤15% bone marrow leukemia blasts\n6. Therapy-related AML\n\niii. Juvenile MyeloMonocytic Leukemia (JMML)\n\n1. JMML in CR1 without CBL mutation\n2. JMML with recurrence of disease with or without CBL mutation\n3. JMML CR2 or beyond\n\niv. Chronic Myeloid Leukemia (CML)\n\n1\\. CML in CR with regard to blast crisis\n\nv. High Risk Myelodysplastic syndrome (MDS)\n\nvi. Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)\n\n1. HL or NHL with a history of induction failure\n2. HL or NHL in PR1 or PR2\n3. HL or NHL in CR2 or subsequent remission\n\nB. Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \\[as determined by the treating physician and approved by the PI\\] may be included).\n\nC. HLA-matched (5-6\u002F6) sibling donor, matched (8-10\u002F10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched).\n\nD. Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients \\>16 years of age and Lansky scores for patients ≤16 years of age.\n\nE. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:\n\ni. Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.\n\nii. Renal: Creatinine clearance or radioisotope GFR ≥60 mL\u002Fmin\u002F1.73 m2 or a serum creatinine based on age\u002Fgender\n\niii. Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA).\n\niv. Hepatic: SGOT (AST) or SGPT (ALT) \\\u003C 5 x upper limit of normal (ULN) for age. Conjugated bilirubin \\\u003C 2.5 mg\u002FdL, unless attributable to Gilbert's Syndrome.\n\nF. Written informed consent obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures.\n\nG. Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy.\n\nH. Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug.\n\nExclusion Criteria:\n\nA. Patients with documented uncontrolled infection\n\nB. Patients who have received allogeneic hematopoietic stem cell transplantation within 6 months, unless being done as a boost.\n\nC. Patients with active ≥Grade 2 aGVHD.\n\nD. Demonstrated lack of compliance with medical care.\n\nE. Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after the last dose of study drug.\n\nF. Females who are known to be pregnant or breastfeeding.\n\nG. History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.\n\nH. Prisoners or subjects who are incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.","ALL","6 Months","39 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study will assess the safety, efficacy, and feasibility of ⍺\u002Fβ CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺\u002Fβ CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.",[26,27,28,29,30,31,32],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Juvenile Myelomonocytic Leukemia","Myelodysplastic Syndromes","Chronic Myeloid Leukemia","Lymphoma, Non-Hodgkin","Lymphoma, Hodgkin",[34,35,36,37],"hematologic malignancy","GVHD","stem cell transplantation","graft manipulation","RECRUITING","2026-06-02",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":42},"2024-05-03",{"date":46,"type":20},"2028-05",{"name":48,"class":49},"University of Florida","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100587054","interrupting-sedentary-time-to-improve-cardiometabolic-health-and-toxicity-in-patients-with-lymphoma-receiving-chemotherapy-the-istand-trial-100587054","NCT06923397","Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign informed consent prior to any study- related procedures.\n* Patients diagnosed with lymphoma.\n* Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.\n* Aged ≥18 years; due to the rarity of the disease in those \\\u003C18 years, this age bracket will not be included.\n* Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.\n* Have physician clearance to participate in exercise.\n* Speak English.\n* Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.\n* Access to a phone that can receive text messages.\n\nExclusion Criteria:\n\n* Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.\n* Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.\n* Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.\n* Patients currently taking weight loss drugs.\n* Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.\n* Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.","18 Years",{"count":59,"type":20},24,[61],"NA","This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.",[64,32,31,65],"Lymphoma","Sedentary Behavior",[64,67,32,31,68,65],"Hodgkin Lymphoma","Non-Hodgkin Lymphoma","2026-04-09",{"date":71,"type":42},"2026-04-13",{"date":73,"type":42},"2025-06-05",{"date":75,"type":20},"2026-12-31",{"name":77,"class":49},"Dana-Farber Cancer Institute",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100294754","prospective-cohort-study-for-lymphoma-samsung-lymphoma-cohort-study-iii-100294754","NCT03117036","Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III","A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center","Inclusion Criteria:\n\n1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas\n2. 20 years\n3. Patients requiring systemic chemotherapy with curative intent\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Myeloid malignancy\n2. Multiple myeloma\n3. Patients do not require systemic chemotherapy with curative intent","20 Years","90 Years",{"count":88,"type":20},600,"3 Years","OBSERVATIONAL","This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.",[31,32],[94,95,96,97],"lymphoma","cohort","serum","cell-free DNA","2025-05-18",{"date":100,"type":42},"2025-05-21",{"date":102,"type":42},"2017-03-01",{"date":104,"type":20},"2026-12-28",{"name":106,"class":49},"Samsung Medical Center","Lymphoma: Hodgkin"]